Macular Telangiectasia Type 2 (MacTel) is a rare eye disease that affects about 250,000 people in the US, mainly between the ages of 43 and 86. The disease causes central vision loss, decreased contrast sensitivity, and glare intolerance. Unlike macular degeneration, MacTel has distinct characteristics and progression patterns.
MacTel’s impact on patients can be significant, with many experiencing reduced reading ability, difficulty driving, and increased need for better lighting. However, recent advancements in treatment have provided new hope for those living with the disease. The FDA-approved Encelto treatment uses cellular therapy to slow down retinal damage by 50%, offering a promising approach to managing MacTel’s progression.
While not a cure, Encelto provides a valuable tool in slowing disease progression and improving quality of life. Patients can expect regular check-ups and surgery to implant the device, which carries rare but manageable risks. Support groups and ongoing research have also improved our understanding and management of MacTel.
For those living with the disease, it’s essential to stay positive and proactive about their care. With advancements in treatment like Encelto, there is always hope for managing the condition and improving vision.
Source: https://www.webmd.com/eye-health/features/expert-qa-macular-telangiectasia